Sanara Medtech Inc
NASDAQ:SMTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sanara Medtech Inc
Income from Continuing Operations
Sanara Medtech Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sanara Medtech Inc
NASDAQ:SMTI
|
Income from Continuing Operations
-$393.1k
|
CAGR 3-Years
64%
|
CAGR 5-Years
38%
|
CAGR 10-Years
12%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Income from Continuing Operations
$175.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Income from Continuing Operations
$1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-53%
|
CAGR 10-Years
-27%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Income from Continuing Operations
$410.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
11%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Income from Continuing Operations
$233.6m
|
CAGR 3-Years
103%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Income from Continuing Operations
$128.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
18%
|
|
Sanara Medtech Inc
Glance View
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 63 full-time employees. The Company’s products include surgical wound care products, which includes CellerateRX Surgical Activated Collagen (Powder and Gel), and chronic wound care products, which include HYCOL Hydrolyzed Collagen (Powder and Gel), BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel. The surgical wound care products are used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, plastic/reconstructive, podiatric, urology and vascular. The chronic wound care products are used across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled nursing facilities, and wound care centers.
See Also
What is Sanara Medtech Inc's Income from Continuing Operations?
Income from Continuing Operations
-393.1k
USD
Based on the financial report for Dec 31, 2025, Sanara Medtech Inc's Income from Continuing Operations amounts to -393.1k USD.
What is Sanara Medtech Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
12%
Over the last year, the Income from Continuing Operations growth was 80%. The average annual Income from Continuing Operations growth rates for Sanara Medtech Inc have been 64% over the past three years , 38% over the past five years , and 12% over the past ten years .
